[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2022000087A1 - Anticuerpo anti-tau y uso del mismo - Google Patents

Anticuerpo anti-tau y uso del mismo

Info

Publication number
CL2022000087A1
CL2022000087A1 CL2022000087A CL2022000087A CL2022000087A1 CL 2022000087 A1 CL2022000087 A1 CL 2022000087A1 CL 2022000087 A CL2022000087 A CL 2022000087A CL 2022000087 A CL2022000087 A CL 2022000087A CL 2022000087 A1 CL2022000087 A1 CL 2022000087A1
Authority
CL
Chile
Prior art keywords
tau antibody
tau
antibody
Prior art date
Application number
CL2022000087A
Other languages
English (en)
Inventor
Seung-Yong Yoon
Original Assignee
Adel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adel Inc filed Critical Adel Inc
Publication of CL2022000087A1 publication Critical patent/CL2022000087A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)

Abstract

ANTICUERPO ANTI-TAU Y USO DEL MISMO
CL2022000087A 2019-07-15 2022-01-12 Anticuerpo anti-tau y uso del mismo CL2022000087A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20190085233 2019-07-15

Publications (1)

Publication Number Publication Date
CL2022000087A1 true CL2022000087A1 (es) 2023-03-10

Family

ID=74088428

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000087A CL2022000087A1 (es) 2019-07-15 2022-01-12 Anticuerpo anti-tau y uso del mismo

Country Status (15)

Country Link
US (1) US20220204601A1 (es)
EP (1) EP4001305A4 (es)
JP (1) JP7595061B2 (es)
KR (1) KR102196840B1 (es)
CN (1) CN114430744B (es)
AU (1) AU2020313751A1 (es)
BR (1) BR112022000719A2 (es)
CA (1) CA3143811A1 (es)
CL (1) CL2022000087A1 (es)
GB (1) GB2600599B (es)
IL (1) IL289813A (es)
MX (1) MX2022000603A (es)
PH (1) PH12022550106A1 (es)
TW (1) TW202116801A (es)
WO (1) WO2021010712A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105121465B (zh) 2013-03-13 2020-09-08 普罗塞纳生物科技公司 Tau免疫疗法
US10752679B2 (en) 2016-05-02 2020-08-25 Prothena Biosciences Limited Tau immunotherapy
IL262726B2 (en) 2016-05-02 2024-07-01 Prothena Biosciences Ltd Antibodies recognizing tau
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
CN119371527A (zh) 2019-03-03 2025-01-28 普罗塞纳生物科学有限公司 识别tau的抗体
US20240376188A1 (en) * 2021-09-09 2024-11-14 The University Of North Carolina At Chapel Hill Monoclonal antibodies targeting acetylated tau and methods of use thereof
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
CN119403819A (zh) * 2022-05-27 2025-02-07 锌医疗公司 新型肽及其用途
AU2023389615A1 (en) 2022-12-08 2025-06-26 Adel, Inc. Fusion comprising anti-tau antibody and peptide and use thereof
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
CN116716352A (zh) * 2023-05-16 2023-09-08 深圳湾实验室 Tau蛋白聚集的细胞模型、其构建方法及应用
CN116693682B (zh) * 2023-06-02 2024-04-19 涌源合生科技(深圳)有限公司 抗Tau蛋白抗体及其制备方法和用途
CN116948025B (zh) * 2023-09-14 2024-04-02 北京凯祥弘康生物科技有限公司 一种抗Tau蛋白的抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130251731A1 (en) * 2012-03-22 2013-09-26 The Trustees Of The University Of Pennsylvania Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies
RU2644242C2 (ru) * 2012-04-05 2018-02-08 Ац Иммуне С.А. Гуманизированное тау-антитело
KR102494798B1 (ko) * 2012-07-03 2023-02-06 워싱턴 유니버시티 Tau에 대한 항체
TWI734975B (zh) * 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
AR103713A1 (es) * 2015-02-26 2017-05-31 Lilly Co Eli Anticuerpos contra tau y sus usos
WO2018106889A1 (en) * 2016-12-09 2018-06-14 Cogwellin L.L.C. Diagnosis of alzheimer's disease
KR102032314B1 (ko) * 2016-12-21 2019-10-16 주식회사 아델 변이된 타우 단백질 단편 및 이의 용도

Also Published As

Publication number Publication date
IL289813A (en) 2022-03-01
PH12022550106A1 (en) 2022-11-21
JP7595061B2 (ja) 2024-12-05
JP2022541539A (ja) 2022-09-26
US20220204601A1 (en) 2022-06-30
GB2600599A (en) 2022-05-04
WO2021010712A1 (ko) 2021-01-21
AU2020313751A1 (en) 2022-02-10
EP4001305A1 (en) 2022-05-25
MX2022000603A (es) 2022-05-20
GB2600599A8 (en) 2024-12-25
CN114430744A (zh) 2022-05-03
EP4001305A4 (en) 2022-10-12
GB2600599B (en) 2025-05-21
GB202201160D0 (en) 2022-03-16
CA3143811A1 (en) 2021-01-21
CN114430744B (zh) 2024-06-21
BR112022000719A2 (pt) 2022-03-29
KR102196840B1 (ko) 2020-12-30
TW202116801A (zh) 2021-05-01
EP4001305A9 (en) 2023-05-24

Similar Documents

Publication Publication Date Title
CL2022000087A1 (es) Anticuerpo anti-tau y uso del mismo
CO2020005981A2 (es) Anticuerpos anti-tau y uso de los mismos
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CL2021000704A1 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 668-2019)
CO2019001980A2 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
CR20190271A (es) Anticuerpos antitau y métodos de uso
CL2021000855A1 (es) Replicones basados en alfavirus para la administración de bioterapias.
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
MX392916B (es) Estructuras de nanofibra y métodos de uso de las mismas
CL2020002540A1 (es) Anticuerpos anti-hla-g y utilización de los mismos
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
CR20170095A (es) Anticuerpos anti-cll-1 e inmunoconjugados referencias recíprocas con solicitudes relacionadas
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
PL3618928T3 (pl) Przeciwciała antysortylinowe i sposoby ich stosowania
IL280317A (en) Anti-avb8 antibodies and compositions and uses thereof
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
MX375020B (es) Anticuerpos anti-alfa-sinucleina y métodos de uso.
DOP2017000236A (es) Neutralización del virus chikungunya mediada por anticuerpos
CL2018001940S1 (es) Automóvil
CL2020002333A1 (es) Anticuerpos anti-klk5 y métodos de uso.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
JOP20200329A1 (ar) بروتينات وشظايا سائدة مناعيا في التصلب المتعدد
CO2022009691A2 (es) Formulaciones líquidas de tasimelteón y métodos para su uso